Anaphylaxis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Anaphylaxis – Pipeline Review, H2 2016’, provides an overview of the Anaphylaxis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaphylaxis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaphylaxis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaphylaxis

The report reviews pipeline therapeutics for Anaphylaxis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaphylaxis therapeutics and enlists all their major and minor projects

The report assesses Anaphylaxis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaphylaxis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaphylaxis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaphylaxis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamis Pharmaceuticals Corp

MannKind Corp

Monosol Rx LLC

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Anaphylaxis Overview 6

Therapeutics Development 7

Pipeline Products for Anaphylaxis - Overview 7

Pipeline Products for Anaphylaxis - Comparative Analysis 8

Anaphylaxis - Therapeutics under Development by Companies 9

Anaphylaxis - Therapeutics under Investigation by Universities/Institutes 10

Anaphylaxis - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Anaphylaxis - Products under Development by Companies 13

Anaphylaxis - Products under Investigation by Universities/Institutes 14

Anaphylaxis - Companies Involved in Therapeutics Development 15

Adamis Pharmaceuticals Corp 15

MannKind Corp 16

Monosol Rx LLC 17

Anaphylaxis - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

epinephrine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

epinephrine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

epinephrine - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

epinephrine - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ET-523 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Anaphylaxis - Dormant Projects 35

Anaphylaxis - Product Development Milestones 36

Featured News & Press Releases 36

Sep 10, 2013: Novel Nasal Epinephrine Shows Comparable Absorption to EpiPen(R) in a Feasibility Study 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Number of Products under Development for Anaphylaxis, H2 2016 7

Number of Products under Development for Anaphylaxis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Anaphylaxis – Pipeline by Adamis Pharmaceuticals Corp, H2 2016 15

Anaphylaxis – Pipeline by MannKind Corp, H2 2016 16

Anaphylaxis – Pipeline by Monosol Rx LLC, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Anaphylaxis – Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for Anaphylaxis, H2 2016 7

Number of Products under Development for Anaphylaxis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports